查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495996

全球内分泌检测市场－2024年至2029年预测

Global Endocrine Testing Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2022年内分泌检测市场规模为114.2亿美元，预计预测期内复合年增长率为6.35%，2029年达到175.74亿美元。

内分泌系统是一组产生荷尔蒙的腺体，有助于调节各种身体功能，包括新陈代谢、性发育、生长和体重。内分泌测试评估荷尔蒙水平并了解内分泌腺的功能。在全球范围内，所有年龄层的荷尔蒙失衡现像都在加剧，这推动了内分泌检测市场的发展。

疾病发生率的增加促进了先进诊断技术的发展，进一步增加了对先进检测方法的需求。儘管这些技术可能很快就会获得市场关注，但与开发相关的巨大成本可能会阻碍快速商业化并限制市场成长。

由于对内分泌检测工具的高需求，市场相关人员正在专注于开发新产品。例如，DRG Diagnostics于2018年10月推出了免费的T4 ELISA检测套组。此 ELISA套件用于直接定量测量人类血清中的游离甲状腺激素。

在全球范围内，糖尿病患者、老年人和肥胖者数量的增加应会推动市场成长。此外，个人健康意识的提高以及政府的支持将增加早期诊断的数量，从而促进内分泌检测市场的成长。由于甲状腺机能低下症和甲状腺功能亢进等疾病，对先进内分泌检测技术的需求预计也会成长。

市场驱动因素：

  • 测量促甲状腺刺激素(TSH) 的检测预计将在内分泌检测市场中成长。

脑下垂体刺激激素 (TSH) 刺激甲状腺产生甲状腺素和三碘甲状腺原氨酸，有助于新陈代谢。 TSH 测试用于测量甲状腺水平。在过去的十年中，甲状腺疾病在世界各地有所增加。根据美国甲状腺协会 (ATA) 估计，2019 年有 2,000 万美国患有某种形式的甲状腺疾病。预计超过 12% 的美国公民在一生中的某个阶段会患上甲状腺疾病。

吸烟、饮酒和烟草使用是甲状腺相关疾病最重要的危险因子。荷兰格罗宁根大学肾内科和格罗宁根大学医学中心的研究人员于 2019 年 11 月进行的一项研究表明，每天吸烟与 TSH 水平较低以及 FT4 和 FT3 水平较低有关。

技术趋势使甲状腺功能测试更具成本效益，甲状腺激素测量最近变得越来越重要。因此，TSH 检测的增加预计将推动内分泌检测市场的成长。

  • 全球老年人口的增加预计将推动内分泌检测市场的成长。

除了与老龄化相关的生长激素下降之外，内分泌系统的变化还包括女性闭经、骨质减少、男性雄激素缺乏以及 2 型糖尿病发生率增加。随着老龄化，内分泌系统会发生一系列影响荷尔蒙水平的变化。这就是为什么全球老年人口的增加是推动内分泌检测市场成长的关键因素之一。

根据联合国2019年世界人口展望资料，世界人口将在30年内翻一番，从77亿增加到97亿，同时人口将快速老化。 65 岁及以上人口数量将从 2019 年的十分之一（9%）增加到 2050 年的六分之一（16%）。此外，3,420 万美国人（略高于十分之一）患有糖尿病。三分之一的美国成年人（约 8,800 万人）患有糖尿病前期。 （图片来源：疾病预防控制中心）

市场限制因素：

  • 高技术成本可能会阻碍内分泌检测市场的成长。

对于内分泌测试製造商来说，研发活动和后续测试商业化的高成本是一个严峻的挑战。因此，监测和诊断个体的荷尔蒙分泌量变得非常昂贵。例如，罗氏公司 2019 财年在研发活动上投资约 116 亿美元。雅培公司的大部分收益都投资于新产品和技术的研发。结果，最终产品非常昂贵，这增加了诊断技术的成本，并对市场产生负面影响。

预计北美市场将主导内分泌检测市场。

北美在内分泌检测市场的主导地位是由先进的医疗基础设施、技术创新、内分泌疾病的高患病率、提高的认识和筛检计划、支持性的法规环境、主要市场参与企业的强大存在以及高医疗支出推动的。美国和加拿大拥有先进的医疗基础设施，导致先进诊断工具和设备的引进和使用。

糖尿病、甲状腺疾病、荷尔蒙失调等内分泌疾病的高盛行率是由于久坐的生活方式、不良的饮食习惯和老化等因素造成的。意识和筛检计划正在鼓励定期内分泌检测，进一步推动需求。

由 FDA 和加拿大卫生署监督的支持性法规环境可促进创新并确保内分泌检测产品的安全性和有效性。美国的高医疗保健支出使个人和医疗机构能够投资于先进的诊断服务，包括内分泌检测，进一步推动市场成长。

主要发展

  • 2023 年 11 月 - 诺和诺德、MEMS 和罗氏合作在马来西亚推出「改变儿童糖尿病」(CDiC)计划。此倡议为儿童和年轻人提供免费的血糖监测用品，是糖尿病管理的重要一步。该倡议还有助于改善获得护理的机会，与今年世界糖尿病日内分泌测试「获得糖尿病护理」一致。
  • 2022 年 5 月 - 总部位于柏林的 Inne.io 获得 930 万欧元资金，用于扩展其荷尔蒙追踪技术。该Start-Ups旨在解决女性医疗保健资金缺乏以及对个人化和数数位化医疗保健的渴望的问题。本轮资金筹措主导。 Inne.io 旨在为各个生命阶段的女性提供服务，并解决女性健康方面的交叉差异，特别是老年女性的健康，她们在医疗保健方面经常被忽视。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行概述

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球内分泌检测市场：依技术分类

  • 介绍
  • 液相层析法质谱法 (LC-MS)
  • 免疫检测
  • ELISA
  • 串联式质谱质谱法
  • 其他的

第六章全球内分泌检测市场：依应用分类

  • 介绍
  • 皮质醇测试
  • 人类绒毛膜促性腺激素分泌（HCG）测试
  • 硫酸去氢表雄酮（DHEAS）测试
  • 甲状腺刺激素（TSH）测试
  • 催乳素测试
  • 胰岛素
  • 其他的

第七章全球内分泌检测市场：依最终用户分类

  • 介绍
  • 医院和诊所
  • 诊断中心

第八章全球内分泌检测市场：按地区

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Randox Laboratories Ltd
  • Abbott
  • Agilent Technologies, Inc
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc
  • F. Hoffmann-La Roche Ltd
  • Beckman Coulter, Inc.
  • Siemens Medical Solutions
  • Thermo Fisher Scientific
简介目录
Product Code: KSI061611696

The global endocrine testing market was valued at US$11.420 billion in 2022 and is expected to grow at a CAGR of 6.35% over the forecast period to reach a total market size of US$17.574 billion by 2029.

An endocrine system is a set of hormone-producing glands that help regulate different body functions, such as metabolism, sexual development, growth, and weight. Endocrine testing involves assessing hormonal levels to determine how the glands are functioning. Globally, hormonal imbalances are increasing among individuals of all ages, which is driving the endocrine testing market.

Increased disease incidence has prompted the development of advanced diagnostic technologies, which further increases the need for sophisticated testing methods. While these technologies are likely to gain some attention in the market shortly, significant costs associated with developing them could hamper their rapid commercialization, thus limiting the market's growth.

Since endocrine testing tools are in high demand, market players are more committed to developing new products. For example, DRG Diagnostics launched free T4 ELISA test kits in October 2018. This ELISA kit is intended to measure free thyroid hormone in human serum directly and quantitatively.

Globally, an increasing number of diabetics, geriatrics, and obese people should promote market growth. In addition, growing health awareness among individuals, along with government support, will increase the number of early diagnoses and thereby contribute to the endocrine testing market growth. The demand for advanced endocrine testing technologies is also expected to grow due to diseases such as hypothyroidism and hyperthyroidism.

Market Drivers:

  • Tests to measure thyroid-stimulating hormone (TSH) are expected to grow the endocrine testing market.

Pituitary-stimulating hormone (TSH) stimulates the production of thyroxine and triiodothyronine by the thyroid gland, which aids metabolism. The TSH test is used to determine thyroid levels. Over the past decade, thyroid disorders have increased worldwide. According to the American Thyroid Association (ATA), 20 million Americans are estimated to have some form of thyroid disease in 2019. More than 12% of US citizens are expected to suffer from thyroid disease at some point in their lives.

Smoking, alcohol consumption, and tobacco use are the most important risk factors for thyroid-related disorders. In a study conducted in November 2019 by researchers from the Department of Nephrology at the University of Groningen and University Medical Center Groningen, The Netherlands, findings showed that daily cigarette smoking was associated with lower levels of TSH and lower levels of FT4 and FT3.

Technology developments have allowed thyroid function tests to become more cost-effective, and thyroid hormone measurement has recently gained importance. As a result, the rise in TSH testing is expected to boost the global endocrine testing market's growth.

  • The rise in the geriatric population worldwide is anticipated to boost the endocrine testing market growth.

In addition to declines in growth hormones associated with aging, changes in the endocrine system include menopause in women, skeletal mass loss, androgen deficiency in men, and an increased incidence of type 2 diabetes. The endocrine system undergoes a series of changes that affect the hormone levels of people as they age. This is why the rise of the global geriatric population is one of the primary factors driving the endocrine testing market's growth.

According to the United Nations (UN) data on World Population Prospects for 2019, the world's population will double within 30 years, from 7.7 billion to 9.7 billion, and at the same time, the world will age more rapidly. The number of people over the age of 65 will rise from one in 11 in 2019 to one in six by 2050 (16%), up from one in 11 at the beginning of this year (9%). Additionally, 34.2 million Americans (just over one in ten) have diabetes. A third of American adults, approximately 88 million, have prediabetes. (Source: CDC)

Market Restraints:

  • The high cost of technology could hinder the endocrine testing market growth.

For endocrine testing manufacturers, the high cost of research and development activities and subsequent commercialization of tests represent a serious challenge. Thus, monitoring and diagnosing an individual's hormone secretion levels has become extremely expensive. Roche, for instance, invested approximately USD 11.6 billion in research and development activities in the financial year 2019. A significant portion of Abbott Laboratories' revenues are invested in the research and development of novel products and technologies. As a result, the end product is very expensive, which adds to the cost of diagnostic technologies, which impacts the market negatively.

The North American market is predicted to dominate the global endocrine testing market.

North America's dominance in the global endocrine testing market is attributed to its advanced healthcare infrastructure, technological innovation, high prevalence of endocrine disorders, rising awareness and screening programs, supportive regulatory environment, strong presence of key market players, and high healthcare spending. The United States and Canada have advanced healthcare infrastructure, leading to the adoption and utilization of advanced diagnostic tools and devices.

The high prevalence of endocrine disorders, such as diabetes, thyroid disorders, and hormonal imbalances, is driven by factors such as sedentary lifestyles, poor dietary habits, and an aging population. Increased awareness and screening programs encourage individuals to undergo regular endocrine testing, further boosting demand.

The supportive regulatory environment, overseen by the FDA and Health Canada, fosters innovation and ensures the safety and efficacy of endocrine testing products. The United States' high healthcare expenditures enable individuals and healthcare institutions to invest in advanced diagnostic services, including endocrine testing, further fuelling market growth.

Key Developments:

  • November 2023- Novo Nordisk, MEMS, and Roche partnered to launch the Changing Diabetes(R) in Children (CDiC) project in Malaysia, aiming to improve care for children and young adults below 25 with type 1 diabetes. The initiative provide free glucose monitoring supplies to children and young adults, is a significant step in diabetes management. The initiative also contribute to improving access to care, aligning with this year's World Diabetes Day theme of "Access to Diabetes Care." The initiative aims to improve the quality of care for children and young adults with type 1 diabetes.
  • May 2022- Berlin-based Inne.io secured €9.3 million in funding to expand its hormone-tracking tech. The startup aims to address the underfunding of women's healthcare and the desire for personalized and digitalized healthcare. The funding was led by DSM Venturing, Borski Fund, Calm Storm Ventures, and high-profile angels Taavet Hinrikus (Wise), Dr Fiona Pathiraja, and Rolf Schromgens (Trivago). Inne.io aims to offer services to women at all stages of life, addressing the intersectional gap in women's health, particularly older women who are often neglected in healthcare.

Segmentation:

By Technology

  • Liquid Chromatography-Mass Spectrometry (LC-MS)
  • Immunoassay
  • ELISA
  • Tandem Mass Spectrometry
  • Others

By Application

  • Cortisol Test
  • Human Chorionic Gonadotropin (HCG) Test
  • Dehydroepiandrosterone Sulfate (DHEAS) Test
  • Thyroid Stimulating Hormone (TSH) Test
  • Prolactin Test
  • Insulin
  • Others

By End Users

  • Hospitals and Clinics
  • Diagnostic Centres

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL ENDOCRINE TESTING MARKET BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Liquid Chromatography-Mass Spectrometry (LC-MS)
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Immunoassay
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. ELISA
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Tandem Mass Spectrometry
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Others
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness

6. GLOBAL ENDOCRINE TESTING MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Cortisol Test
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Human Chorionic Gonadotropin (HCG) Test
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Dehydroepiandrosterone Sulfate (DHEAS) Test
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Thyroid Stimulating Hormone (TSH) Test
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Prolactin Test
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness
  • 6.7. Insulin
    • 6.7.1. Market Opportunities and Trends
    • 6.7.2. Growth Prospects
    • 6.7.3. Geographic Lucrativeness
  • 6.8. Others
    • 6.8.1. Market Opportunities and Trends
    • 6.8.2. Growth Prospects
    • 6.8.3. Geographic Lucrativeness

7. GLOBAL ENDOCRINE TESTING MARKET BY END USERS

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Diagnostic Centres
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness

8. GLOBAL ENDOCRINE TESTING MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By End Users
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Technology
    • 8.3.2. By Application
    • 8.3.3. By End Users
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Technology
    • 8.4.2. By Application
    • 8.4.3. By End Users
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Others
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Technology
    • 8.5.2. By Application
    • 8.5.3. By End Users
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Technology
    • 8.6.2. By Application
    • 8.6.3. By End Users
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. South Korea
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Taiwan
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Thailand
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Indonesia
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Japan
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Randox Laboratories Ltd
  • 10.2. Abbott
  • 10.3. Agilent Technologies, Inc
  • 10.4. bioMerieux SA
  • 10.5. Bio-Rad Laboratories, Inc
  • 10.6. F. Hoffmann-La Roche Ltd
  • 10.7. Beckman Coulter, Inc.
  • 10.8. Siemens Medical Solutions
  • 10.9. Thermo Fisher Scientific